Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18109633 | 0.80 | LMNA (0.39) | KMT2AKDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL22715337 | 0.73 | LMNA (0.37) | KMT2AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL29439593 | 0.73 | LMNA (0.37) | KMT2AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL5746102 | 0.69 | ALDH1A1 (0.40) | KMT2AKDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL30421541 | 0.69 | ALDH1A1 (0.40) | KMT2AKDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL29439648 | 0.68 | CDC7 (0.40) | KDM4EHSP90AA1LMNAALDH1A1MAPT | |
| SCHEMBL22715698 | 0.68 | CDC7 (0.40) | KDM4EHSP90AA1LMNAALDH1A1MAPT | |
| SCHEMBL13271049 | 0.67 | NQO2 (0.42) | KDM4EHSP90AA1HSP90AB1LMNASMN1; SMN2 | |
| SCHEMBL140640 | 0.66 | — | — | |
| SCHEMBL150686 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| EP-3722297-A1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | Gilead Sciences, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3321265-B1 | 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR UTILISATION AS MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190282576-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10285990-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3321265-A1 | 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR UTILISATION AS MODULATORS OF TOLL-LIKE RECEPTORS | Gilead Sciences, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3097102-B1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | SRC 1225/4885KMT2A 1716/4885KDM4E 1694/4885 |
| US-10285990-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | SRC 1225/4885KMT2A 1716/4885KDM4E 1694/4885 |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | SRC 1225/4885KMT2A 1716/4885KDM4E 1694/4885 |
| US-20190282576-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | SRC 1225/4885KMT2A 1716/4885KDM4E 1694/4885 |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | SRC 1225/4885KMT2A 1716/4885KDM4E 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.